QGEN logo

Qiagen N.V. Stock Price

NYSE:QGEN Community·US$7.3b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 21 Fair Values set on narratives written by author

QGEN Share Price Performance

US$35.17
35.17 (0.00%)
US$38.00
Fair Value
US$35.17
35.17 (0.00%)
7.4% undervalued intrinsic discount
US$38.00
Fair Value
Price US$35.17
AnalystLowTarget US$38.00
AnalystConsensusTarget US$53.53
AnalystHighTarget US$55.91

QGEN Community Narratives

·
Fair Value US$38 7.4% undervalued intrinsic discount

Latent Tuberculosis And Research Pressures Will Constrain Progress Yet Long-Term Prospects Remain Intact

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
·
Fair Value US$53.53 34.3% undervalued intrinsic discount

QGEN: Future Results Will Depend On Automation And Gradual Sentiment Recovery

0users have liked this narrative
0users have commented on this narrative
11users have followed this narrative
·
Fair Value US$55.91 37.1% undervalued intrinsic discount

Latent TB Testing Expansion And Automation Will Support Stronger Long Term Prospects

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
US$38
7.4% undervalued intrinsic discount
Revenue
4.28% p.a.
Profit Margin
23.84%
Future PE
17.58x
Price in 2029
US$47.98

Trending Discussion

Updated Narratives

QGEN logo

Latent TB Testing Expansion And Automation Will Support Stronger Long Term Prospects

Fair Value: US$55.91 37.1% undervalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
QGEN logo

Latent Tuberculosis And Research Pressures Will Constrain Progress Yet Long-Term Prospects Remain Intact

Fair Value: US$38 7.4% undervalued intrinsic discount
1 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
QGEN logo

QGEN: Expect Balance Sheet Strength To Support Oncology And Diagnostic Platform Expansion

Fair Value: US$53.53 34.3% undervalued intrinsic discount
11 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Undervalued with excellent balance sheet.

1 Risk
4 Rewards

Qiagen N.V. Key Details

US$2.1b

Revenue

US$710.6m

Cost of Revenue

US$1.4b

Gross Profit

US$986.1m

Other Expenses

US$402.2m

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
1.94
66.15%
19.16%
50.0%
View Full Analysis

About QGEN

Founded
1984
Employees
5500
CEO
Thierry Bernard
WebsiteView website
www.qiagen.com

Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.

Recent QGEN News & Updates

New Narrative May 15

Latent TB Testing Expansion And Automation Will Support Stronger Long Term Prospects

Catalysts About Qiagen Qiagen provides molecular diagnostics, sample preparation and bioinformatics tools used in clinical testing and research. What are the underlying business or industry changes driving this perspective?

Recent updates

No updates